Houston medical device startup names new CEO

now at the helm

Houston-based Saranas has tapped a new leader amidst push to commercialize bleed detection technology. Photo via LinkedIn

Houston-based medical device company Saranas has tapped a veteran of the healthcare industry as its new CEO.

Mike MacKinnon most recently was president and partner at Madison Ventures +, a private equity firm based in Greenwood Village, Colorado. The firm invests in companies in healthcare, real estate, finance, and other sectors.

Before joining Madison Ventures +, MacKinnon was CEO of Zidan Medical, a startup focused on treatment of airway lesions in patients with early stage lung cancer. He served in that role from 2019 to 2023.

Earlier, he was CEO of ROX Medical, a medical device company specializing in minimally invasive vascular therapy for patients with uncontrolled high blood pressure. He held that role from 2018 to 2019. He previously worked at Philips North America, Volcano, AtheroMed, Hansen Medical, Access Closure, and FoxHollow Technologies.

In a news release, Dan Wolterman, chairman of Saranas’ board and former president and CEO of Memorial Hermann Health System, calls MacKinnon “an accomplished executive with an impressive record of bringing disruptive technology to market, guiding strategy, and driving significant growth.”

Now president and CEO of Nashua, New Hampshire-based medical device company Conformal Medical, James Reinstein was president and CEO of Saranas from 2020 to 2022. Prior to Reinstein, Zaffer Syed held that position from 2017 to 2020. He's still an adviser for the company and recently announced his role as entrepreneur in residence at the Texas Medical Center.

Saranas is working on commercializing its Early Bird Bleed Monitoring System, touted as the first and only system FDA-approved bleeding detection system for procedures involving blood vessels. It is designed to detect bleeds early, enabling physicians to reduce medical risks and potentially avoid costly medical problems.

“Bleeding remains a common issue during and after endovascular procedures and can result in life-threatening complications,” says MacKinnon.

Since being founded in 2013, Saranas has treated over 1,200 patients with its device and has received $29.2 million in funding, according to Crunchbase. This includes a $12.8 million Series B round that Saranas got in 2021 from Chicago-based Baird Capital and Austin-based S3 Ventures.

The Early Bird device was developed at Houston’s Texas Heart Institute. The FDA approved the device in 2019.

James Reinstein joins the Houston Innovators Podcast to discuss what's next for growing medical device company, Saranas. Photo courtesy

Health tech executive leads Houston startup into its next generation following $12.8M series B

houston innovators podcast episode 103

When James Reinstein took the helm of Houston-based Saranas in March 2020, he was tasked with taking the medical device company through its series B funding round and into larger clinical trials. Navigating these tasks during a global pandemic wasn't part of the plan.

"There was just so much uncertainty," Reinstein says on this week's episode of the Houston Innovators Podcast. "All of the funds didn't know which end was up, what hospitals would be doing, what procedures were going to begin again."

Saranas received FDA approval and began its clinical trials for its Early Bird Bleed Monitoring System in 2019. The device is designed to detect and track bleeding complications related to endovascular procedures. These medical procedures treat problems, such as aneurysms, that affect blood vessels. Around 20 percent of patients suffer a bleeding complication during endovascular procedures.

Reinstein explains that the way health tech funding trended over the past 18 months greatly affected Saranas. The device fell outside the parameters of what investors were looking for during this pandemic time. However, Reinstein explains, the Early Bird worked and had FDA approval — that made all the difference.

"We are very confident that the product does work and it can have a significant impact for hospitals and patients," Reinstein says. "Eventually, the term sheets came in."

Saranas announced in July that it closed a $12.8 million series B investment led by Wisconsin-based Baird Capital, the venture capital and global private equity arm of Baird, a global company with a location in Houston. Austin-based S3 Ventures also supported the round.

The funds will propel Saranas into its next phase, which includes growing its team, larger trials, and a next-generation product.

Reinstein has had decades in health care innovation all over the world, with a large chunk of his career at Boston Scientific. He's seen Houston's innovation ecosystem evolve.

"I do think that there's a great potential for Houston to really develop the industry," Reinstein says. "There's just two areas that need to get fortified. One is the funding and getting the funds directed to Houston companies — with the idea that the company stays in Houston. ... The other side of the coin is really finding the talent to come in and run the companies, take on leadership positions."

Reinstein shares more details on what's next for Saranas, as well as his advice for med tech entrepreneurs and observations on Houston's innovation ecosystem on the show. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.


The results are in for Houston-based Saranas' clinical trials. Courtesy of Saranas

Houston early bleeding detection device company reveals results of its clinical trials

blood tests

A Houston-based startup is closer to taking flight with a medical device designed to catch bleeding complications during medical procedures that involve blood vessels.

On May 22, researchers presented the results of a study showing the Early Bird Bleed Monitoring System from Houston-based Saranas Inc. detected various levels of bleeding in 63 percent of the patients who underwent endovascular procedures. These procedures treat problems, such as aortic aneurysms, that affect blood vessels.

No troubles were reported with the Early Bird device during the clinical trial, the researchers say.

Before this study, the Early Bird device hadn't been tested in humans. In all, 60 patients in five states participated in the clinical trial, which ran from August to December last year. Findings of the study were unveiled at the Society for Cardiovascular Angiography Interventions 2019 Scientific Sessions in Las Vegas.

The study's authors say they plan to continue evaluating the device at medical institutions that want to better manage bleeding during endovascular procedures.

"This is the first time we're seeing how this device could help in a real-world patient setting, and we were very encouraged by the results. Right now, patients have a risk of vessel injury when undergoing endovascular procedures where the femoral artery or vein is used for vascular access," Dr. Philippe Genereux, principal investigator for the study and a cardiologist at Morristown Medical Center in Morristown, New Jersey, says in a news release.

"This technology allows us to detect bleeding in real-time," Genereux adds, "which means we can take action quickly and improve the outcomes of the procedure and recovery for the patient."

In March, the Early Bird device — invented at Houston's Texas Heart Institute — received the U.S. Food and Drug Administration's approval as a "novel" medical device.

Saranas says Early Bird is the first and only device of its type. The FDA approval and the promising results of the clinical trial pave the way for the eventual launch of the device into the healthcare market.

A forecast from professional services firm KPMG predicts the global market for medical devices will reach nearly $800 billion by 2030. Early Bird aims to capture a sliver of that market by addressing an expensive and potentially fatal problem. One-fifth of patients experience bleeding complications during large-bore endovascular procedures. Research shows these complications are associated with a greater risk of death, longer hospital stays, and higher healthcare costs.

The Early Bird device is meant to decrease those complications by quickly alerting medical professionals to signs of bleeding during endovascular procedures.

As explained by the Texas Heart Institute, the Early Bird employs a sheath — a plastic tube that helps keep arteries and vessels open — embedded with sensors that measure the electrical resistance across a blood vessel. When the Early Bird senses a change in the electrical resistance, medical professionals receive audible and visual notifications about potential internal bleeding. If detected early, this bleeding can be minimized.

Altogether, Saranas has raised $12 million from investors, including a $2.8 million round in May 2018. The company was founded in 2013.

"What attracted me to Saranas is that our solution has the potential to meaningfully reduce serious bleeding complications that worsen clinical outcomes and drive up healthcare costs," says Zaffer Syed, who joined the startup as president and CEO in 2017. "In addition, our device may support access of important minimally invasive cardiac procedures by allowing them to be performed more safely."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Tesla poised to bring ‘megafactory’ to Houston area with 1,500 jobs

Tesla Talk

Tesla is expected to bring a “megafactory” and 1,500 manufacturing jobs to the Houston area.

According to various news reports this week, Tesla intends to spend $200 million on a facility in Brookshire, Texas. The Waller County Commissioners Court approved tax abatements on March 5 for the new plant.

“We are super excited about this opportunity—1,500 advanced manufacturing jobs in the county and in the city," Waller County Precinct 4 Commissioner Justin Beckendorff said during Wednesday’s Commissioners Court meeting.

Tesla will lease two buildings in Brookshire's Empire West Business Park. According to documents from Waller County, Tesla will add $44 million in facility improvements. In addition, it will install $150 million worth of manufacturing equipment.

As part of the deal, Tesla will invest in property improvements that involve a 600,000-square-foot, $31 million manufacturing facility that will house $2 million worth of equipment and include improvements to the venue.

The facility will produce Tesla megapacks, which are powerful batteries to provide energy storage and support, according to the company. A megapack can store enough energy to power about 3,600 homes for one hour.

Tesla can receive a 60 percent tax abatement for 10 years. According to the tax abatement agreement, Tesla has to employ at least 1,500 people by 2028 in order to be eligible for the tax break.

In addition to the employment clause, Tesla also will be required to have a minimum of $75 million in taxable inventory by January 1, 2026, which will increase to $300 million after three years.

9 innovation & networking events for Houstonians to attend at SXSW 2025

A Houstonian's Guide to SXSW

South by Southwest, Austin's signature hybrid music, film and interactive festival, returns to the Texas capital this month, running March 7 through 15.

In the business and innovation sector, the festival fuses together SXSW Edu for educators at the beginning of the week and SXSW Interactive, which is one of the largest gatherings in the world of innovators, technologists, artists, startups, investors and policy-makers. SXSW is a powerful international magnet for creators and the people who serve them.

I started coming to Austin for SXSW in 1999, a few years after the Interactive portion (nicknamed "Spring Break for Nerds") launched and when the entire conference of 6,000 attendees fit into the Austin Convention Center. Back then, you could rub shoulders with famous bloggers who challenged established tech journalists in the hallways, multimedia artists handing out bootleg CD-ROMS, and hard-core geeks setting web standards and laws related to technology that we enjoy today.

SXSW, like Austin itself, has grown up quite a bit in the last two decades and has fended off the common Austin refrain of "It was better X years ago," as everything has become more commercial, less "authentic" and more expensive. SXSW officially sells tickets or badges for $2295.00 at the Platinum level (with cheaper options as well) providing access to stand in lines with hundreds of your friends for the most popular keynotes and panels.

One critical tradition of SXSW and part of the relentless motivation to "Keep Austin Weird" is the dozens of unofficial side events that pop up during the event all across the city. These unofficial events and activations typically provide networking opportunities fueled by the draw of internet-famous speakers, free food, and free alcohol. As SXSW has grown exponentially, it still seems to retain its charm and quirkiness as not quite a music festival, like Bonnaroo or Lollapalooza, nor a film festival like Sundance or Tribeca, and certainly not a traditional tech conference like CES. I like to think of it as a Carnival with many things to do and see but without a specific agenda or outcome. Since COVID and the financial market retraction, these parties and happy hours have become a lot more restrained, but they still exist if you know where to look.

This article is designed to guide you through the highlights, both official and unofficial, of SXSW with a focus on professional business development with a strong bent toward networking with tech startups. Here's what not to miss.

Friday, March 7

Equitech Texas Welcome Breakfast
9–11 a.m.
Inn Cahoots, 1221 E 6th St.
A breakfast gathering of people involved with Impact Investing and Equity Tech, led by Laurie Felker Jones

Startup Superconnector featuring Practice Pitch
11 a.m.–4 p.m.
Funded House, 315 Lavaca St.
This is a "Pop Up Pitch" event designed to help startups with their investor pitches by putting them in the same room with investors and professional service providers.

Startup Crawl at SXSW 2025
5 p.m. for Backstage VIP
6–9 p.m.
Capital Factory, 701 Brazos St., Suite 1600

Startup Crawl is arguably the most important unofficial event during SXSW where hundreds of startups showcase their offerings in a huge trade show, party format.

Saturday, March 8

The Red ThreadX
607 W. Third Street, 29th Floor
Curated content, strategic connections and actionable insights for military and defense-oriented businesses

SXSW 2025: Dolphin Tank
8–10:30 a.m.
FQ Lounge: Waller Creek Boathouse, 74 Trinity St.
In partnership with Amazon and The Female Quotient, this event is dedicated to championing women entrepreneurs.

Sunday, March 9

2025 TXST SXSW Lab: The Bobcat Den
1:30–8:00 p.m.
The Bobcat Den @ SXSW, Q-Branch 200 E. Sixth St., Suite 310
PROMO CODE: MICHAELBESTVIP
The TXST SXSW Lab: The Bobcat Den is a dynamic, all-day event that showcases Texas State University’s cutting-edge research, industry collaborations, and student innovation.

Monday, March 10

Founded in Texas - For Women Founders
9 a.m.–12:30 p.m.
Brown Advisory, 200 W. Sixth St., Suite 1700
Project W, The Artemis Fund, HearstLab and Brown Advisory have joined forces to bring you Founded in Texas, an investor feedback session designed to support Texas-based women who are founders of B2B and B2B2C technology companies.

Inaugural Texas House
11:00 a.m. on Monday, March 10, until 11:59 p.m. on Tuesday March 11
315 Lavaca St.
More than ever, Texans are leading at the frontiers of technology, entrepreneurship, and culture. See the full agenda

Tuesday, March 11

Super Connectors Meet Up
4–5 p.m.
Hilton Austin Downtown, 500 E. Fourth St.,Room 412
*Badge-only event
"Superconnectors," tor those who seem hyper-connected to large networks of people, are naturally drawn to SXSW. They thrive in a creative and innovative environment, affording them countless opportunities to meet interesting people. Meet some here.

---

This information and more can be found at Marc Nathan's VIP Insider’s Guide to SXSW.


Houston space tech co.'s lunar lander touches down on moon — condition unknown

Lunar Landing

A privately owned lunar lander touched down on the moon Thursday, but as the minutes dragged on, flight controllers could not confirm its condition or whether it was even upright near the south pole.

The last time Intuitive Machines landed a spacecraft on the moon, a year ago, it ended up sideways.

The company's newest Athena lander dropped out of lunar orbit as planned, carrying an ice drill, a drone and two rovers for NASA and others. The hourlong descent appeared to go well, but it took a while for Mission Control to confirm touchdown.

“We're on the surface,” reported mission director and co-founder Tim Crain. A few minutes later, he repeated, "It looks like we're down ... We are working to evaluate exactly what our orientation is on the surface.”

Launched last week, Athena was communicating with controllers more than 230,000 miles away and generating solar power, officials said. But nearly a half-hour after touchdown, Crain and his team still were unable to confirm if everything was all right with the 15-foot lander. NASA and Intuitive Machines abruptly ended their live webcast, promising more updates at a news conference later in the afternoon.

“OK team, keep working the problem," Crain urged.

Intuitive Machines last year put the U.S. back on the moon despite its lander tipping on its side.

Another U.S. company Firefly Aerospace on Sunday became the first to achieve complete success with its commercial lunar lander. A vacuum already has collected lunar dirt for analysis and a dust shield has shaken off the abrasive particles that cling to everything.

Intuitive Machines was aiming this time for a mountain plateau just 100 miles from the south pole, much closer than before.

This week's back-to-back moon landings are part of NASA’s commercial lunar delivery program meant to get the space agency’s experiments to the gray, dusty surface and jumpstart business. The commercial landers are also seen as scouts for the astronauts who will follow later this decade under NASA's Artemis program, the successor to Apollo.

NASA officials said before the landing that they knew going in that some of the low-cost missions would fail. But with more private missions to the moon, that increased the number of experiments getting there.

NASA spent tens of millions of dollars on the ice drill and two other instruments riding on Athena, and paid an additional $62 million for the lift. Most of the experiments were from private companies, including the two rovers. The rocket-powered drone came from Intuitive Machines — it's meant to hop into a permanently shadowed crater near the landing site in search of frozen water.

Intuitive Machines' Trent Martin said before the flight that Athena needed to land upright in order for the drone and rovers to deploy.

To lower costs even more, Intuitive Machines shared its SpaceX rocket launch with three spacecraft that went their separate ways. Two of them — NASA’s Lunar Trailblazer and AstroForge’s asteroid-chasing Odin — are in jeopardy.

NASA said this week that Lunar Trailblazer is spinning without radio contact and won’t reach its intended orbit around the moon for science observations. Odin is also silent, with its planned asteroid flyby unlikely.

As for Athena, Intuitive Machines made dozens of repairs and upgrades following the company’s sideways touchdown by its first lander. It still managed to operate briefly, ending America’s moon-landing drought of more than 50 years.

Until then, the U.S. had not landed on the moon since Apollo 17 in 1972. No one else has sent astronauts to the moon, the overriding goal of NASA’s Artemis program. And only four other countries have successfully landed robotic spacecraft on the moon: Russia, China, India and Japan.

View All Listings